An assessment by the Statin Intolerance Panel: 2014 update
An assessment by the Statin Intolerance Panel: 2014 update
复制标题
DOI：
10.1016/j.jacl.2014.03.002
复制
发表时间：
2014-06-01
影响因子：
4.4
通讯作者：
Jacobson, Terry A.
中科院分区：
文献类型：
--
作者：
Guyton, John R.;Bays, Harold E.;Jacobson, Terry A.
这篇来自国家脂质协会他汀类药物不耐受小组的文章为理解他汀类药物不耐受提供了一个框架，并为卫生专业人员提出了一般性建议。有关与肌肉、肝脏、认知和葡萄糖代谢相关的不良事件的具体指导，应参考他汀类药物安全工作组的其他报告。尽管他汀类药物的不良反应很少导致永久性后遗症，但症状性不耐受经常阻碍他汀类药物降低心血管风险。我们在这里强调临床医生的咨询作用，帮助每个患者对他汀类药物的耐受性做出个人决定。我们确定了进一步研究他汀类药物不耐受的迫切需要，并对研究设计提出了建议。(C)2014年全国油脂协会。版权所有。
This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design. (C) 2014 National Lipid Association. All rights reserved.